Biedrba "Apvienba HIV.LV"+371 26062077 (ik dienu pl. 9 - 21)
apvieniba@apvienibahiv.lv

 
   
112714

TDF/3TC aizsargefekts
Apskatt komentrus (0)


12.07.2020


HIV pozitvie pacienti ir mazk jutgi pret Covid-19, ja vii lieto tenofovra (TDF form)/emtricitabna kombinciju, liecina Spnij veikt kohortas ptjuma rezultti.
Ptjums tika veikts 60 klniks, kas atrodas dads valsts das, un taj piedaljs 77590 pacientu, kuriem diagnosticts HIV. 236 no viiem tika diagnosticts Covid-19, no kuriem 151 tika nogdts slimncs (15 nonca intensvs terapijas nodas, 20 cilvki nomira).
Ptjuma rezultti liecina, ka risks saslimt ar Covid-19 HIV pacientiem nav lielks k prjai populcijai. Turklt tie, kuri lieto tenofovru (TDF)/emtricitabnu (FTC) (kombincija, ko izmanto HIV infekcijas rstanai un HIV pirmskontakta profilaksei), ir mazk jutgi pret Covid-19 nek pacienti, kas rstti, izmantojot citas shmas.
urnl Annals of Internal Medicine publict ptjuma autori uzskata, ka nepiecieami papildu testi, lai apstiprintu dadu antiretrovrusu prepartu efektivitti Covid-19 rstan. o datu apstiprinana btu liels sasniegums, lai novrstu medicnas personla un cilvku no pa riska grupu inficanos.
Spnij vairk nek 90% HIV pozitvu cilvku saem antiretrovrusu terapiju.
**************************
Source: Annals of Internal Medicine | Incidence and Severity of Covid-19 in HIV-Positive Persons Receiving Antiretroviral Therapy. A Cohort Study | https://www.acpjournals.org/doi/10.7326/M20-3689 |
<... Abstract
Background:
The incidence and severity of coronavirus disease 2019 (Covid-19) among HIV-positive persons receiving antiretroviral therapy (ART) have not been characterized in large populations.
Objective:
To describe the incidence and severity of Covid-19 by nucleos(t)ide reverse transcriptase inhibitor (NRTI) use among HIV-positive persons receiving ART.
Design:
Cohort study.
Setting:
HIV clinics in 60 Spanish hospitals between 1 February and 15 April 2020.
Participants:
77 590 HIV-positive persons receiving ART.
Measurements:
Estimated risks (cumulative incidences) per 10 000 persons and 95% CIs for polymerase chain reactionconfirmed Covid-19 diagnosis, hospitalization, intensive care unit (ICU) admission, and death. Risk and 95% CIs for Covid-19 diagnosis and hospital admission by use of the NRTIs tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC), tenofovir alafenamide (TAF)/FTC, abacavir (ABC)/lamivudine (3TC), and others were estimated through Poisson regression models.
Results:
Of 77 590 HIV-positive persons receiving ART, 236 were diagnosed with Covid-19, 151 were hospitalized, 15 were admitted to the ICU, and 20 died. The risks for Covid-19 diagnosis and hospitalization were greater in men and persons older than 70 years. The risk for Covid-19 hospitalization was 20.3 (95% CI, 15.2 to 26.7) among patients receiving TAF/FTC, 10.5 (CI, 5.6 to 17.9) among those receiving TDF/FTC, 23.4 (CI, 17.2 to 31.1) among those receiving ABC/3TC, and 20.0 (CI, 14.2 to 27.3) for those receiving other regimens. The corresponding risks for Covid-19 diagnosis were 39.1 (CI, 31.8 to 47.6), 16.9 (CI, 10.5 to 25.9), 28.3 (CI, 21.5 to 36.7), and 29.7 (CI, 22.6 to 38.4), respectively. No patient receiving TDF/FTC was admitted to the ICU or died.
Limitation:
Residual confounding by comorbid conditions cannot be completely excluded.
Conclusion:
HIV-positive patients receiving TDF/FTC have a lower risk for Covid-19 and related hospitalization than those receiving other therapies. These findings warrant further investigation in HIV preexposure prophylaxis studies and randomized trials in persons without HIV. ...>




 
      Atpaka

atstj tuku: atstj tuku:
vrds:




Ievadiet drobas kodu:

Visual CAPTCHA